The Medicines Company (MDCO) 25.49 $MDCO
Technical Coverage on Pharma Equities -- Research on Allergan, Actavis, Medicines Co., and Akorn
PR Newswire - Fri May 09, 10:30AM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, and the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Actavis PLC (NYSE: ACT), The Medicines Company (NASDAQ: MDCO) and Akorn Inc. (NASDAQ: AKRX). Free technical research on AGN, ACT, MDCO and AKRX can be downloaded upon signing up at:
The Medicines Company to Host Surgery and Perioperative Care Investor and Analyst Meeting on May 22
Business Wire - Thu May 08, 11:09AM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled a surgery and perioperative care investor and analyst meeting for Thursday, May 22, 2014 from 8:30 am to 12:00 noon. The event will be held at the Company's Global Center 1 at 8 Sylvan Way in Parsippany, NJ. The meeting is being hosted to highlight The Medicines Company's second emerging core business of surgery and perioperative care.
Shares of MDCO Down 27.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue May 06, 4:54PM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 3 months, Medicines Co has returned 27.65% as of today's recent price of $26.14.
The Medicines Company to Participate in 2014 Bank of America Global Healthcare Conference
Business Wire - Tue May 06, 12:58PM CDT
The Medicines Company (NASDAQ: MDCO) is scheduled to present at the 2014 Bank of America Healthcare Conference in Las Vegas, NV on May 13th at 9:20 AM Pacific Time / 12:20 PM Eastern Time.
CRL for The Medicines Co.'s Cangrelor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:05PM CDT
The FDA issued a CRL to The Medicines Co.'s (MDCO) NDA for cangrelor.
The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions
Marketwire - Thu May 01, 10:02AM CDT
The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced today the presentation of new pre-clinical data from ALN-PCSsc, targeting PCSK9 for the treatment of hypercholesterolemia. These data are being presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions being held May 1-3 in Toronto, Ontario.
The Medicines Company Receives Complete Response Letter From FDA Requesting Additional Information for New Drug Application for Its Antiplatelet Agent Cangrelor
Marketwire - Wed Apr 30, 6:44PM CDT
The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Company's new drug application (NDA) for its investigational intravenous antiplatelet agent cangrelor.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Generic Drugs Industry Announces Earnings Results, Leadership Appointments, and Conference Participation - Analyst Notes on Mylan, Zoetis, Hospira, Horizon Pharma and The Medicines Co
PR Newswire - Wed Apr 30, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan, Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS), Hospira Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP) and The Medicines Co. (NASDAQ: MDCO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1816-100free.
Downtrend Call Working As Medicines Co Stock Falls 27.2% (MDCO)
Comtex SmarTrend(R) - Tue Apr 29, 11:01AM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 3 months, Medicines Co has returned 27.23% as of today's recent price of $26.29.
Critical Alerts For American Express, Time Warner, Nasdaq OMX Group, The Medicines Company, and PetSmart By InvestorsObserver
PR Newswire - Fri Apr 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AXP, TWX, NDAQ, MDCO, and PETM.
The Medicines Co.'s Q1 Earnings Surpass Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 10:40AM CDT
The Medicines Co. (MDCO) also announced an acquisition agreement which reflects its efforts to diversify its portfolio and reduce its dependence on Angiomax.
The Medicines Company reports rise of 25% in adjusted net income & 14% in revenues in Q1 2014
M2 - Thu Apr 24, 5:08AM CDT
Hospital company The Medicines Company (NASDAQ:MDCO) stated on Wednesday that its adjusted net income was USD22.1m (USD0.33 per share) for its first quarter 2014.
Interesting MDCO Put And Call Options For June 21st
DividendChannel.com - Wed Apr 23, 10:18AM CDT
Investors in Medicines Co saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDCO options chain for the new June 21st contracts and identified one put...
The Medicines Company Adds Novel, Approved, Surgical Sealant to Its Surgical Hemostasis Portfolio
Marketwire - Wed Apr 23, 6:02AM CDT
The Medicines Company (NASDAQ: MDCO) and Tenaxis Medical, Inc. (Tenaxis) today announced an agreement for The Medicines Company to acquire Tenaxis. Tenaxis's sole product, which mechanically seals both human tissue and artificial grafts is approved, but not launched in the US -- having received US PMA approval from the FDA in March 2013 as a vascular sealant. The product is also approved with a European CE Mark as a surgical sealant applicable to cardiovascular, general, urological, and thoracic surgery. The addition of the Tenaxis product adds another solution for surgical bleeding to The Medicines Company's portfolio which also includes the marketed product, RecoThrom (aqueous, recombinant human Thrombin) and the investigational product, Fibrocaps (a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery) which has completed phase III trials and is under FDA and EMA review.
The Medicines Company Reports First Quarter 2014 Financial Results
Marketwire - Wed Apr 23, 6:02AM CDT
The Medicines Company (NASDAQ: MDCO), a global company focused on saving lives, alleviating suffering, and improving the economic efficiency of the world's leading hospitals, today announced first quarter financial results for 2014.
Medicines Co Shares Down 28.3% Since SmarTrend's Sell Call (MDCO)
Comtex SmarTrend(R) - Tue Apr 22, 9:40AM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 3 months, Medicines Co has returned 28.29% as of today's recent price of $25.91.
THE MEDICINES COMPANY 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against the Medicines Company - MDCO
GlobeNewswire - Fri Apr 18, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until April 22, 2014 to file lead plaintiff applications in a securities class action lawsuit against The Medicines Company (Nasdaq:MDCO). Investor losses must relate to purchases of the Company's securities during the period between the period of February 20, 2013 and February 12, 2014, inclusive. This action is pending in the United States District Court for the District of New Jersey.
Downgrade Alert for Medicines Co (MDCO)
Comtex SmarTrend(R) - Thu Apr 17, 7:56AM CDT
Medicines Co (NASDAQ:MDCO) was downgraded from Outperform to Market Perform at Leerink today. The stock closed yesterday at $24.90 on volume of 692,000 shares, below average daily volume of 1.3 million. Medicines Co (NASDAQ:MDCO) has potential upside of 30.0% based on a current price of $24.90 and analysts' consensus price target of $32.38. The stock should find initial resistance at its 50-day moving average (MA) of $29.06 and further resistance at its 200-day MA of $33.06.
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
Technical Coverage on Pharma Equities -- Research on Allergan, Actavis, Medicines Co., and Akorn
PR Newswire - Fri May 09, 10:30AM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, and the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Actavis PLC (NYSE: ACT), The Medicines Company (NASDAQ: MDCO) and Akorn Inc. (NASDAQ: AKRX). Free technical research on AGN, ACT, MDCO and AKRX can be downloaded upon signing up at:
The Medicines Company to Host Surgery and Perioperative Care Investor and Analyst Meeting on May 22
Business Wire - Thu May 08, 11:09AM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled a surgery and perioperative care investor and analyst meeting for Thursday, May 22, 2014 from 8:30 am to 12:00 noon. The event will be held at the Company's Global Center 1 at 8 Sylvan Way in Parsippany, NJ. The meeting is being hosted to highlight The Medicines Company's second emerging core business of surgery and perioperative care.
Shares of MDCO Down 27.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue May 06, 4:54PM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 3 months, Medicines Co has returned 27.65% as of today's recent price of $26.14.
The Medicines Company to Participate in 2014 Bank of America Global Healthcare Conference
Business Wire - Tue May 06, 12:58PM CDT
The Medicines Company (NASDAQ: MDCO) is scheduled to present at the 2014 Bank of America Healthcare Conference in Las Vegas, NV on May 13th at 9:20 AM Pacific Time / 12:20 PM Eastern Time.
CRL for The Medicines Co.'s Cangrelor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:05PM CDT
The FDA issued a CRL to The Medicines Co.'s (MDCO) NDA for cangrelor.
The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions
Marketwire - Thu May 01, 10:02AM CDT
The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced today the presentation of new pre-clinical data from ALN-PCSsc, targeting PCSK9 for the treatment of hypercholesterolemia. These data are being presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions being held May 1-3 in Toronto, Ontario.
The Medicines Company Receives Complete Response Letter From FDA Requesting Additional Information for New Drug Application for Its Antiplatelet Agent Cangrelor
Marketwire - Wed Apr 30, 6:44PM CDT
The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Company's new drug application (NDA) for its investigational intravenous antiplatelet agent cangrelor.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Generic Drugs Industry Announces Earnings Results, Leadership Appointments, and Conference Participation - Analyst Notes on Mylan, Zoetis, Hospira, Horizon Pharma and The Medicines Co
PR Newswire - Wed Apr 30, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan, Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS), Hospira Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP) and The Medicines Co. (NASDAQ: MDCO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1816-100free.
Downtrend Call Working As Medicines Co Stock Falls 27.2% (MDCO)
Comtex SmarTrend(R) - Tue Apr 29, 11:01AM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 3 months, Medicines Co has returned 27.23% as of today's recent price of $26.29.
Critical Alerts For American Express, Time Warner, Nasdaq OMX Group, The Medicines Company, and PetSmart By InvestorsObserver
PR Newswire - Fri Apr 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AXP, TWX, NDAQ, MDCO, and PETM.
The Medicines Co.'s Q1 Earnings Surpass Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 10:40AM CDT
The Medicines Co. (MDCO) also announced an acquisition agreement which reflects its efforts to diversify its portfolio and reduce its dependence on Angiomax.
The Medicines Company reports rise of 25% in adjusted net income & 14% in revenues in Q1 2014
M2 - Thu Apr 24, 5:08AM CDT
Hospital company The Medicines Company (NASDAQ:MDCO) stated on Wednesday that its adjusted net income was USD22.1m (USD0.33 per share) for its first quarter 2014.
Interesting MDCO Put And Call Options For June 21st
DividendChannel.com - Wed Apr 23, 10:18AM CDT
Investors in Medicines Co saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDCO options chain for the new June 21st contracts and identified one put...
The Medicines Company Adds Novel, Approved, Surgical Sealant to Its Surgical Hemostasis Portfolio
Marketwire - Wed Apr 23, 6:02AM CDT
The Medicines Company (NASDAQ: MDCO) and Tenaxis Medical, Inc. (Tenaxis) today announced an agreement for The Medicines Company to acquire Tenaxis. Tenaxis's sole product, which mechanically seals both human tissue and artificial grafts is approved, but not launched in the US -- having received US PMA approval from the FDA in March 2013 as a vascular sealant. The product is also approved with a European CE Mark as a surgical sealant applicable to cardiovascular, general, urological, and thoracic surgery. The addition of the Tenaxis product adds another solution for surgical bleeding to The Medicines Company's portfolio which also includes the marketed product, RecoThrom (aqueous, recombinant human Thrombin) and the investigational product, Fibrocaps (a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery) which has completed phase III trials and is under FDA and EMA review.
The Medicines Company Reports First Quarter 2014 Financial Results
Marketwire - Wed Apr 23, 6:02AM CDT
The Medicines Company (NASDAQ: MDCO), a global company focused on saving lives, alleviating suffering, and improving the economic efficiency of the world's leading hospitals, today announced first quarter financial results for 2014.
Medicines Co Shares Down 28.3% Since SmarTrend's Sell Call (MDCO)
Comtex SmarTrend(R) - Tue Apr 22, 9:40AM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on January 29th, 2014 at $36.13. In approximately 3 months, Medicines Co has returned 28.29% as of today's recent price of $25.91.
THE MEDICINES COMPANY 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against the Medicines Company - MDCO
GlobeNewswire - Fri Apr 18, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until April 22, 2014 to file lead plaintiff applications in a securities class action lawsuit against The Medicines Company (Nasdaq:MDCO). Investor losses must relate to purchases of the Company's securities during the period between the period of February 20, 2013 and February 12, 2014, inclusive. This action is pending in the United States District Court for the District of New Jersey. Downgrade Alert for Medicines Co (MDCO)
Comtex SmarTrend(R) - Thu Apr 17, 7:56AM CDT
Medicines Co (NASDAQ:MDCO) was downgraded from Outperform to Market Perform at Leerink today. The stock closed yesterday at $24.90 on volume of 692,000 shares, below average daily volume of 1.3 million. Medicines Co (NASDAQ:MDCO) has potential upside of 30.0% based on a current price of $24.90 and analysts' consensus price target of $32.38. The stock should find initial resistance at its 50-day moving average (MA) of $29.06 and further resistance at its 200-day MA of $33.06.
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
